Intech Investment Management LLC Has $1.06 Million Stake in Scholar Rock Holding Corporation $SRRK

Intech Investment Management LLC reduced its holdings in Scholar Rock Holding Corporation (NASDAQ:SRRK) by 37.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 28,513 shares of the company’s stock after selling 16,778 shares during the quarter. Intech Investment Management LLC’s holdings in Scholar Rock were worth $1,062,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. Norges Bank acquired a new position in shares of Scholar Rock during the 2nd quarter worth about $41,628,000. Balyasny Asset Management L.P. bought a new position in Scholar Rock in the 2nd quarter worth approximately $33,062,000. Federated Hermes Inc. increased its position in Scholar Rock by 232.1% in the 3rd quarter. Federated Hermes Inc. now owns 800,455 shares of the company’s stock worth $29,809,000 after buying an additional 559,455 shares during the period. Bellevue Group AG lifted its holdings in shares of Scholar Rock by 17.6% during the second quarter. Bellevue Group AG now owns 2,947,295 shares of the company’s stock worth $104,393,000 after buying an additional 440,405 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Scholar Rock by 161.0% during the third quarter. JPMorgan Chase & Co. now owns 713,988 shares of the company’s stock worth $26,589,000 after buying an additional 440,401 shares during the last quarter. 91.08% of the stock is currently owned by institutional investors.

Scholar Rock Stock Performance

Shares of NASDAQ SRRK opened at $45.29 on Friday. The firm has a market capitalization of $5.20 billion, a price-to-earnings ratio of -13.20 and a beta of 0.70. Scholar Rock Holding Corporation has a one year low of $22.71 and a one year high of $49.82. The business has a fifty day simple moving average of $45.32 and a 200 day simple moving average of $39.35. The company has a current ratio of 6.95, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.10. During the same quarter last year, the company posted ($0.64) EPS. Sell-side analysts expect that Scholar Rock Holding Corporation will post -2.42 EPS for the current year.

Analyst Ratings Changes

SRRK has been the topic of several research analyst reports. Barclays raised their price objective on shares of Scholar Rock from $52.00 to $53.00 and gave the stock an “overweight” rating in a research note on Tuesday. Raymond James Financial reissued a “strong-buy” rating on shares of Scholar Rock in a report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a report on Thursday, January 22nd. Wolfe Research started coverage on shares of Scholar Rock in a research report on Tuesday, November 18th. They set an “outperform” rating and a $42.00 price objective for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Scholar Rock in a research note on Thursday, December 11th. Four research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $54.14.

Insider Activity at Scholar Rock

In related news, CEO David Hallal sold 57,450 shares of the stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $42.70, for a total value of $2,453,115.00. Following the completion of the transaction, the chief executive officer owned 1,541,645 shares of the company’s stock, valued at $65,828,241.50. This represents a 3.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Vikas Sinha sold 16,755 shares of the firm’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total transaction of $715,438.50. Following the transaction, the chief financial officer owned 583,245 shares of the company’s stock, valued at approximately $24,904,561.50. This represents a 2.79% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 208,470 shares of company stock worth $9,201,778 in the last ninety days. Company insiders own 13.30% of the company’s stock.

Key Headlines Impacting Scholar Rock

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: FDA & commercial progress for apitegromab creates a clear commercial pathway and longer?term revenue upside, a material catalyst for the stock. Scholar Rock outlines 2026 apitegromab BLA resubmission and commercial launch following FDA progress
• Positive Sentiment: Recent quarterly results beat consensus (EPS of -$0.76 vs. -$0.86) and triggered a large volume spike, evidence of investor interest and potential momentum. Scholar Rock (NASDAQ:SRRK) Sees Large Volume Increase After Strong Earnings
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $58 price target while raising several medium? and long?term EPS forecasts (FY2027–FY2030), signaling continued analyst conviction in the company’s longer?term outlook. Scholar Rock (NASDAQ:SRRK) Earns “Buy” Rating from HC Wainwright
• Neutral Sentiment: HC Wainwright made a mix of small upward revisions to several quarterly estimates (Q1–Q3 2026) but these are modest improvements and mostly reflect modeling tweaks rather than changed guidance from the company.
• Negative Sentiment: HC Wainwright lowered FY2026 and Q4?2026 EPS estimates (Q4 2026 from -$0.64 to -$0.82; FY2026 to -$3.55 from -$3.45), increasing near?term uncertainty and likely contributing to selling pressure despite the long?term upgrades.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).